Insulet reports Q2 EPS 38c, consensus 26c

Reports Q2 revenue $396.5M, consensus $385.0M. “Our second quarter achievements demonstrate the strength and value of our pioneering offerings and dedicated team,” said Jim Hollingshead, President and Chief Executive Officer. “Omnipod 5 continues to disrupt the diabetes market in the U.S. and has received a fantastic market response internationally with its commercial launch in the UK. We are also very well-positioned in the type 2 market, which is currently driven by Omnipod DASH and soon to be joined by Omnipod GO and ultimately Omnipod 5. We continue to deliver on our mission to improve the lives of people with diabetes, and we are just getting started.”